AstraZeneca Clinches FDA Nod for First All-Oral, Time-Limited Leukemia Therapy
AstraZeneca (NASDAQ:AZN) announced on Friday that the U.S. Food and Drug Administration (FDA) has approved its BTK inhibitor, Calquence (acalabrutinib), in combination with venetoclax as the first all-oral, fixed-duration treatment for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)












